Nautilus Biotechnolgy, Inc. Common Stock (NAUT) Stock Price
NAUTStock
$2.06+92.52%52W
Market Cap$261.78M
P/E—
PEG Ratio—
Div yield—
Beta0.75
NAUT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.59%
Price vs S&P 500 (4W)117.10%
VGM Score71.52
NAUT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.14 | -$0.11 | +21.43%(+$0.03) | |
| Q1 2026 | -$0.14 | -$0.12 | +17.24%(+$0.02) | |
| Q4 2025 | -$0.14 | -$0.11 | +21.43%(+$0.03) | |
| Q3 2025 | -$0.15 | -$0.11 | +26.67%(+$0.04) | |
| Q2 2025 | -$0.14 | -$0.12 | +14.29%(+$0.02) |
NAUT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.25
4.25
4.25
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
NAUTNautilus Biotechnolgy, Inc. Common Stock | — | — | B | — | — | — | — | $2.06 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Nautilus Biotechnolgy, Inc. Common Stock
Nautilus Biotechnology develops a platform technology for high-throughput proteomics analysis, providing researchers with integrated tools to study the human proteome at scale. The company's offerings include proprietary mass spectrometry systems, reagent kits, and analysis software designed for research, diagnostics, and drug development. As a development-stage company, Nautilus aims to expand access to comprehensive protein analysis and accelerate advances in human health and medicine.